标题
B-Raf and the inhibitors: from bench to bedside
作者
关键词
Melanoma, Sorafenib, Papillary Thyroid Carcinoma, Mutant BRAF, Vemurafenib
出版物
Journal of Hematology & Oncology
Volume 6, Issue 1, Pages 30
出版商
Springer Nature
发表日期
2013-04-25
DOI
10.1186/1756-8722-6-30
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- MEK and the inhibitors: from bench to bedside
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells
- (2012) Chung-Pu Wu et al. BIOCHEMICAL PHARMACOLOGY
- BRAFmutation testing in clinical practice
- (2012) James Ziai et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- A High Percentage ofBRAFV600EAlleles in Papillary Thyroid Carcinoma Predicts a Poorer Outcome
- (2012) Anna Guerra et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- BRAFV600EMutation and Papillary Thyroid Cancer: Chicken or Egg?
- (2012) Mingzhao Xing JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Clinical Implication of Highly Sensitive Detection of theBRAFV600E Mutation in Fine-Needle Aspirations of Thyroid Nodules: A Comparative Analysis of Three Molecular Assays in 4585 Consecutive Cases in aBRAFV600E Mutation-Prevalent Area
- (2012) Seung-Tae Lee et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma
- (2012) Giovanni Ponti et al. Journal of Hematology & Oncology
- Current management and novel agents for malignant melanoma
- (2012) Byung Lee et al. Journal of Hematology & Oncology
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma
- (2012) Frank Stenner et al. ONCOLOGY
- Allele Specific Locked Nucleic Acid Quantitative PCR (ASLNAqPCR): An Accurate and Cost-Effective Assay to Diagnose and Quantify KRAS and BRAF Mutation
- (2012) Luca Morandi et al. PLoS One
- Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation
- (2011) L. Xi et al. BLOOD
- Mutant BRAF Melanomas—Dependence and Resistance
- (2011) Poulikos I. Poulikakos et al. CANCER CELL
- Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
- (2011) F. Su et al. CANCER RESEARCH
- Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
- (2011) H. Yang et al. CANCER RESEARCH
- Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse
- (2011) R.-P. Charles et al. CANCER RESEARCH
- Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
- (2011) N. Jin et al. CLINICAL CANCER RESEARCH
- Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma
- (2011) J. J. Luke et al. CLINICAL CANCER RESEARCH
- Role of BRAF in Thyroid Oncogenesis
- (2011) L. M. Caronia et al. CLINICAL CANCER RESEARCH
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- The Primary Occurrence ofBRAFV600EIs a Rare Clonal Event in Papillary Thyroid Carcinoma
- (2011) Anna Guerra et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Targeting insulin-like growth factor axis in hepatocellular carcinoma
- (2011) Jennifer Wu et al. Journal of Hematology & Oncology
- Optimized Allele-Specific Real-Time PCR Assays for the Detection of Common Mutations in KRAS and BRAF
- (2011) Alois H. Lang et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- BRAFMutations in Hairy-Cell Leukemia
- (2011) Enrico Tiacci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection ofBRAFMutations in Thyroid Nodules by Allele-Specific PCR Using a Dual Priming Oligonucleotide System
- (2010) Hee Jin Lee et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- RAF protein-serine/threonine kinases: Structure and regulation
- (2010) Robert Roskoski BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response
- (2010) C. A. Pratilas et al. CLINICAL CANCER RESEARCH
- From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
- (2010) Christophe Frémin et al. Journal of Hematology & Oncology
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
- (2009) K. P. Hoeflich et al. CANCER RESEARCH
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- (2009) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- BrafV600E cooperates with Pten loss to induce metastatic melanoma
- (2009) David Dankort et al. NATURE GENETICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started